Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit
By BY MIHIR ZAVERI AND KATIE THOMAS
Health
https://ift.tt/31YDhZP
A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
New York Times
your-feed-science, Drugs (Pharmaceuticals), Suits and Litigation (Civil), Fines (Penalties)
October 9, 2019 at 01:47AM